skip to main content
Ngôn ngữ:
Giới hạn tìm kiếm: Giới hạn tìm kiếm: Dạng tài nguyên Hiển thị kết quả với: Hiển thị kết quả với: Dạng tìm kiếm Chỉ mục

0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

International journal of molecular sciences, 2022-12, Vol.24 (1), p.554 [Tạp chí có phản biện]

2022 by the authors. 2022 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms24010554 ;PMID: 36613994

Tài liệu số/Tài liệu điện tử

Trích dẫn Trích dẫn bởi
  • Nhan đề:
    0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
  • Tác giả: Sosne, Gabriel ; Kleinman, Hynda K ; Springs, Clark ; Gross, Robert Hollis ; Sung, Jihye ; Kang, Shinwook
  • Chủ đề: clinical trial ; Cornea - metabolism ; Corneal Dystrophies, Hereditary - metabolism ; corneal healing ; Double-Blind Method ; Humans ; Keratitis - drug therapy ; neurotrophic keratopathy ; ocular discomfort ; Ophthalmic Solutions - pharmacology ; Thymosin - metabolism ; thymosin ß4 ; Treatment Outcome ; Trigeminal Nerve Diseases - metabolism
  • Là 1 phần của: International journal of molecular sciences, 2022-12, Vol.24 (1), p.554
  • Mô tả: We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathy. Complete healing occurred after 4 weeks in 6 of the 10 RGN-259-treated subjects and in 1 of the 8 placebo-treated subjects ( = 0.0656), indicating a strong efficacy trend. Additional efficacy was seen in the significant healing ( = 0.0359) with no recurrent defects observed at day 43, two weeks after cessation of treatment, while the one healed placebo-treated subject at day 28 suffered a recurrence at day 43. The Mackie classification disease stage improved in the RGN-259-treated group at Days 29, 36, and 43 ( = 0.0818, 0.0625, and 0.0467, respectively). Time to complete healing also showed a trend towards efficacy ( = 0.0829, Kaplan-Meier) with 0.1% RGN-259. RGN-259-treated subjects had significant improvements at multiple time points in ocular discomfort, foreign body sensation, and dryness which were not seen in the placebo group. No significant adverse effects were observed. In summary, the use of 0.1% RGN-259 promotes rapid healing of epithelial defects in neurotrophic keratopathy, improves ocular comfort, and is safe for treating this challenging population of patients.
  • Nơi xuất bản: Switzerland: MDPI
  • Ngôn ngữ: English
  • Số nhận dạng: ISSN: 1422-0067
    ISSN: 1661-6596
    EISSN: 1422-0067
    DOI: 10.3390/ijms24010554
    PMID: 36613994
  • Nguồn: MEDLINE
    PubMed Central
    ProQuest Central
    DOAJ Directory of Open Access Journals
Trở lại danh sách kết quả
Về trang trướcTrước Kết quả  11 Tiếp theoTới trang tiếp theo
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Đang tìm Cơ sở dữ liệu bên ngoài...